Impact of delay of local control in nonmetastatic extremity primary osteosarcoma.
local control
low middle-income countries
osteosarcoma
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
02
10
2023
received:
03
01
2023
accepted:
17
10
2023
medline:
24
11
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
ppublish
Résumé
The timing of local control (LC) is not well studied in osteosarcoma. We assessed the impact of the delay of LC on the survival outcome of patients with osteosarcoma. We conducted a retrospective analysis of children (≤18 years) with nonmetastatic extremity primary osteosarcoma at King Hussein Cancer Center from January 2005 until March 2020. Patients' demographics, disease characteristics, and outcomes were collected. Events were defined as death, progression, or relapse. Cox proportional hazards regression was used for univariable and multivariable comparisons of different covariates. Eighty-two patients were included; 41 (50%) were females; the median age was 12.5 years (range: 5.9-18). Sixty-four patients (78%) underwent LC by limb-salvage surgery. Fifteen patients (18%) had a delay of LC greater than or equal to 18 weeks. After a median follow-up of 54 months (range: 8-188), the 5-year event-free survival (EFS) and overall survival (OS) were 55.3% ± 5.8% and 66.6% ± 6%, respectively. On univariable analysis, LC greater than or equal to 18 weeks, progression before LC, amputation, and poor histologic response were associated with worse EFS (p = .007, .007, .006, .002) and OS (p = .01, .001, .006, .004). On multivariable analysis, LC greater than or equal to 18 weeks, progression before LC, and poor histologic response were associated with worse EFS (p < .001, .007, .002); and OS (p < .001, .007, .008). Male gender was associated with worse OS on univariable and multivariable analysis (both p = .02). After exclusion of patients with early progression before Week 11, good histologic response and LC less than 18 weeks were associated with better EFS (p = .04 and .03). While good histologic response was associated with better OS (p = .02), LC less than 18 weeks was not significant (p = .2). Our findings suggest that delay in LC could have an impact on the outcomes in patients with osteosarcoma. However, further investigations involving larger sample sizes and longer follow-up are necessary to fully comprehend the extent of this influence.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30752Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Cole S, Gianferante M, Zhu B, Mirabello L. Osteosarcoma: a Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017. Cancer. 2022;128(11):2107-2118.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029-3035. doi:10.1200/JCO.2014.59.4895
Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol. 1984;2(6):617-624. doi:10.1200/JCO.1984.2.6.617
Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26(2):407-414. doi:10.1093/annonc/mdu526
Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36-50. doi:10.1016/j.ejca.2018.11.027
O'Kane GM, Cadoo KA, Walsh EM, et al. Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review. Clin Sarcoma Res. 2015;5(1):1-8. doi:10.1186/s13569-015-0032-0
Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10(1):5-15. doi:10.1200/JCO.1992.10.1.5
Ferrari S, Palmerini E, Staals EL, et al. The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future. Cancer Treat Res. 2009;152:275-287. doi:10.1007/978-1-4419-0284-9_14
Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18(24):4016-4027. doi:10.1200/JCO.2000.18.24.4016
Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396-1408. doi:10.1016/S1470-2045(16)30214-5
Gorlick R, Janeway K, Lessnick S, et al. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer. 2013;60(6):1009-1015. doi:10.1002/pbc.24429.Children
Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97(12):3068-3075. doi:10.1002/cncr.11456
Enneking WF. An abbreviated history of orthopaedic oncology in North America. Clin Orthop Relat Res. 2000;374(374):115-124. doi:10.1097/00003086-200005000-00010
Chauhan A, Joshi GR, Chopra BK, Ganguly M, Reddy GR. Limb salvage surgery in bone tumors: a retrospective study of 50 cases in a single center. Indian J Surg Oncol. 2013;4(3):248-254. doi:10.1007/s13193-013-0229-8
Choong PFM, Sim FH. Limb-sparing surgery for bone tumors: new developments. Semin Surg Oncol. 1997;13(1):64-69. doi:10.1002/(SICI)1098-2388(199701/02)13:1<64::AID-SSU10>3.0.CO;2-9
Ebeid W, Amin S, Abdelmegid A. Limb salvage management of pathologic fractures of primary malignant bone tumors. Cancer Control. 2005;12(1):57-61. doi:10.1177/107327480501200107
Bielack BSS, Kempf-bielack B, Exner GU, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776-790.
Tsuda Y, Tsoi K, Parry MC, et al. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. Bone Joint J. 2020;102(6):795-803. doi:10.1302/0301-620X.102B6.BJJ-2019-1307.R1
Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004-2011. doi:10.1200/JCO.2005.06.031
Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15(1):76-84. doi:10.1200/JCO.1997.15.1.76
Petrilli AS, De Camargo B, Odone Filho V, et al. Results of the Brazilian osteosarcoma treatment group studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006;24(7):1161-1168. doi:10.1200/JCO.2005.03.5352
Samuel G, Yadav A, Mounisamy P, Kayal S. An audit of delays in the management of nonmetastatic osteosarcoma at a tertiary care center in South India. Cureus. 2022;14(8):e27744. doi:10.7759/cureus.27744
Mittal A, Pushpam D, Ganguly S, et al. Controversies and challenges in the management of osteosarcoma-an Indian perspective. Indian J Surg Oncol. 2022;13(4):939-955.
Gaston CL, Taleon K, Bersales K, et al. The effect of a patient navigator on treatment abandonment and follow-up for high grade osteosarcoma patients in the Philippine General Hospital. Asian Pacific J Cancer Prev. 2021;22(9):2873-2877. doi:10.31557/APJCP.2021.22.9.2873
Meazza C, Luksch R, Daolio P, et al. Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents. Med Oncol. 2014;31(4):4-9. doi:10.1007/s12032-014-0875-x
Rosen G, Caparros B, Huvos A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1986;49:1221-1230.
Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21(8):1574-1580. doi:10.1200/JCO.2003.08.165
Hegyi M, Semsei A, Jakab Z, et al. Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer. 2011;57(3):415-422.
Ali BA, Salman M, Ghanem KM, et al. Clinical prognostic factors and outcome in pediatric osteosarcoma: effect of delay in local control and degree of necrosis in a multidisciplinary setting in Lebanon. J Glob Oncol. 2019;5:1-8. doi:10.1200/JGO.17.00241
Bacci G, Ferrari S, Longhi A, Mellano D, Giacomini S, Forni C. Delay in diagnosis of high-grade osteosarcoma of the extremities. Has it any effect on the stage of disease? Tumori. 2000;86(3):204-206. doi:10.1177/030089160008600305
Sneppen O, Hansen LM. Presenting symptoms and treatment delay in osteosarcoma and Ewing's sarcoma. Acta Oncol (Madr). 1984;23(2-3):159-162. doi:10.3109/02841868409136005
Yang JYK, Cheng FWT, Wong KC, et al. Initial presentation and management of osteosarcoma, and its impact on disease outcome. Hong Kong Med J. 2009;15(6):434-439.
Vasquez L, Silva J, Chavez S, et al. Prognostic impact of diagnostic and treatment delays in children with osteosarcoma. Pediatr Blood Cancer. 2020;67(4):e28180. doi:10.1002/pbc.28180
Kundu ZS, Gogna P, Gupta V, Kamboj P, Singla R, Sangwan SS. Proximal humeral reconstruction using nail cement spacer in primary and metastatic tumours of proximal humerus. Strategies Trauma Limb Reconstr. 2013;8(3):149-154. doi:10.1007/s11751-013-0172-9
Rafalla AA, Abdullah ESA. Endoprosthetic replacement versus cement spacer in reconstruction of proximal humerus after tumor resection: cost and benefits. J Orthop Surg. 2017;25(2):2309499017713937. doi:10.1177/2309499017713937
Puri A, Gulia A, Pruthi M, Koushik S. Primary cement spacers: a cost-effective, durable limb salvage option for knee tumors. Knee. 2012;19(4):320-323. doi:10.1016/j.knee.2011.06.012
Kyriacou S, Parratt M, Pollock R. Novel use of a hip spacer to perform reconstruction following extra-articular scapula resection for sarcoma. J Surg Case Rep. 2012;2012(9):14. doi:10.1093/jscr/2012.9.14
Shahpari O, Mousavian A, Elahpour N, Malahias MA, Ebrahimzadeh MH, Moradi A. The use of antibiotic impregnated cement spacers in the treatment of infected total joint replacement: challenges and achievements. Arch Bone Jt Surg. 2020;8(1):11-20. doi:10.22038/abjs.2019.42018.2141
Donati D, Giacomini S, Gozzi E, et al. Knee arthrodesis with a temporary spacer performed in malignant tumor around the knee. Arch Orthop Trauma Surg. 2002;122(2):123-128. doi:10.1007/s004020100327
Capanna R, Biagini R, Ruggieri P, Bettelli G, Casadei R, Campanacci M. Temporary resection-arthrodesis of the knee using an intramedullary rod and bone cement. Int Orthop. 1989;13(4):253-258. doi:10.1007/BF00268507